The role of RGS2 (regulator of G-protein signalling 2) has been studied in several tumours. The purpose of the present study is to investigate the correlations between clinicopathological factors and patients' survival time and RGS2 expression in stage II and III CRC (colorectal cancer) patients. Real-time quantitative PCR was performed in 36 CRC tissues with recurrence and 28 without recurrence, and in three CRC-metastasis-derived cell lines (SW620, LoVo and Colo205) and 3 primary-CRC-derived ones (SW480, Caco-2 and HCT116) to examine RGS2 mRNA expression. In addition, to provide visualized evidence for RGS2 mRNA expression, random CRC samples were also performed with RT-PCR (reverse transcription-PCR). RGS2 protein was detected by immunostaining in 118 paraffin-embedded specimens, and the correlations between clinicopathological factors and survival time and RGS2 expression were analysed. We found that RGS2 mRNA was down-regulated both in CRC tissues with recurrence and metastasisderived cell lines, and the expression level of RGS2 was unrelated to gender, age, tumour grade, or lymphovascular or perineural invasion. However, it was positively related to disease-free survival time (P < 0.05). Furthermore, low RGS2 expression indicated a poorer survival rate (P < 0.05, log-rank test). Multivariate analysis also showed that weak RGS2 protein expression was an independent adverse prognosticator in CRC (P < 0.05). Taken together, we suggested that down-regulation of RGS2 might play an important role in CRC metastasis and predict poor prognosis in stage II and III CRC patients.
INTRODUCTION
CRC (colorectal cancer) is the third most common cancer in the world and the fourth most common cause of cancer-related death [1] . Stage II and III tumours together represent approx. 70 % of CRC patients. Although surgery, standard care and postoperation chemotherapy successfully induce clinical remission in approx. 60 % of stage II and III cases, 40-50 % of patients will relapse, and most of them will die from secondary diseases [2, 3] . The pathological stage, the histological grade and the tumour histology constitution are important prognostic factors. However, they are not enough to evaluate clinical outcome adequately, and it is therefore important to identify prognostic factors that may predict poor outcome in stage II and III CRC patients and guide postoperation adjuvant therapy.
RGS2 (regulator of G-protein signalling 2), like other members of the RGS family, possesses an RGS domain that mediates
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its GAPs (GTPase-activating proteins) activity towards G-protein subunits (G q ), which activates phospholipase C intracellularly to exert a biological effect. RGS2 was first identified in a screen for activation genes in human lymphocytes [4] , and its expression has been shown to be regulated by several cell stressors [5] [6] [7] , the cell cycle [7] and the differentiation state of cells [5] . RGS2 protein was involved in a variety of cellular functions including the regulation of blood pressure [8, 9] and neurological functions [10] [11] [12] [13] . Recently, several studies have reported the emerging role of RGS2 in experimental tumours [14] [15] [16] [17] [18] . However, the clinical significance of RGS2 expression in tumours remains unclear.
In the present study, we investigated RGS2 expression using real-time quantitative PCR, RT-PCR (reverse transcription-PCR and immunohistochemistry. Then, the correlations between RGS2 expression and clinicopathological features and survival time were analysed. 
MATERIALS AND METHODS

Patients and tissue specimens
Cell lines
Six human CRC cell lines were obtained from A.T.C.C. (Manassas, VA, U.S. A.) . Three were primary-CRC-derived cell lines (SW480, Caco-2 and HCT116), two lymph-node-metastasisderived cell lines (SW620 and LoVo) and one an abdominal dropsy-metastasis-derived cell line (Colo205). Cell lines LoVo and Colo205 were cultured in RPMI 1640 medium (Gibco BRL/Life Technologies, Gaithersburg, MD, U.S. A.) , and Caco-2 and HCT116 cell lines were cultured in Eagle's minimum essential medium (Gibco BRL/Life Technologies) and McCoy's 5a medium (Gibco BRL/Life Technologies) modified respectively. Both SW480 and SW620 were cultured in Leibovitz's L-15 medium (Gibco BRL/Life Technologies). All media were supplemented with 10 % (v/v) fetal bovine serum (Gibco), 100 IU (international units)/ml penicillin and 100 μg/ml streptomycin at 37
• C in a 5% CO 2 humidified atmosphere.
mRNA analysis by RT-PCR and real-time quantitative PCR
Total RNA was isolated with an RNeasy Mini kit (Qiagen, Hilden, Germany) and treated with DNase. cDNAs were synthesized with Oligo-dT primers (Promega, Madison, WI, U.S.A.) according to the manufacturer's instructions. The RGS2-specific primers used were 5 -AAGATTGGAAGACCCGTTTGAG-3 (forward) and 5 -GCAAGACCATATTTGCTGGCT-3 (reverse). GAPDH (glyceraldehyde-3-phosphate dehydrogenase) served as a control for RNA intensity and was amplified using primers 5 -GAAGGTGAAGGTCGGAGTC-3 (forward) and 5 -GAAGATGGTGATGGGATTTC-3 (reverse). The following PCR thermocycling conditions were used: 1 cycle at 95
• C for 15 min; 30 cycles at 94
• C for 30 s, 57
• C for 30 s and 72
• C for 30 s; and final extension at 72
• C for 7 min. Real-time PCRs were carried out using the default PCR cycle on a sequence detection system, namely ABI Prism 7900HT (Applied Biosystems), and the amplified cDNA was detected by SYBR Green I dye (Qiagen). Results were analysed using ABI Prism 7900 SDS software (Sequence Detection System 2.0; Applied Biosystems). Ratios of the intensities of the target gene and GAPDH signals were used as a relative measure of the expression level of the target gene; primer sequences of RGS2 and GAPDH for real-time quantitative PCR analysis were the same as those for RT-PCR. All experiments were repeated three times. A.) . For the study, 4 μm sections from archival paraffin blocks were deparaffinized and heated twice, for 10 min each, in a microwave oven (500 W) before exposure to the first antibody. Immunoperoxidase staining was carried out using the two-step EnVision TM method (Dako, Glostrup, Denmark) according to the manufacturer's instructions and visualized with 3,3 -diaminobenzidine tetrachloride (Sigma, St. Louis, MO, U.S. A.) . The omission of primary bodies was used to prepare negative control samples.
Cytoplasm staining was measured for this antibody. Positive cells were counted by two pathologists who were blind to the clinical outcome. For clinicopathological correlation, we used a four-tiered scoring system (negative to 3+), which took into account the percentage of positive cells and staining intensity. We separately interpreted RGS2 -and 1+ as 'low expression' and RGS2 2+ and 3+ as 'strong expression'.
Statistical analysis
We used Stata version 8.0 (StataCorp LP) for statistical analysis. The association among categorical data was analysed by using the χ 2 test. ROC (receiver-operating characteristics) curves were established to evaluate the diagnostic value of RGS2 mRNA for differentiating between CRCs with recurrence and those without recurrence. Survival curves were generated by the Kaplan-Meier method, and univariate survival distributions were compared with the use of the log-rank test. The multivariate Cox proportional hazards model was used for detection of independent prognosticators. The two-tailed P value for significance was established at 0.05.
RESULTS
RGS2 expression was associated with recurrence in stage II and III CRC
In 64 fresh samples, the mRNA level of RGS2 was significantly lower in stage II and III CRC tissues with recurrence compared with those without recurrence (P = 0.025; Figure 1a) . The performance of the established value of mRNA expression was evaluated by the ROC analysis and calculation of the prediction accuracy. The ROC curve is the graphical representation of this reciprocal relationship between sensitivity and specificity, calculated for all possible threshold values; each operating point on the ROC curve represents the combination of sensitivity and specificity at a given threshold value [19] . In the present study, ROC analysis showed that the best cutoff value to distinguish between CRCs with recurrence and those without recurrence was 0.00125. The AUC (area under ROC), which is a measure of the diagnostic accuracy, was 0.748 [95 % CI (confidence interval) 0.572-0.925, P < 0.05; Figure 2 ]. When the cutoff value was set at 0.00125, the Youden's index (sensitivity + specificity-1) reached the largest value (0.293). The sensitivity was 66.7 %; the specificity was 85.7 %; the prediction accuracy was 71.4 %. To provide visualized evidence for RGS2 mRNA expression, random CRC samples were also used in RT-PCR and the same results were obtained (Figure 1b) . Relative quantities of RGS2 mRNA in CRC cell lines were expressed as N-fold difference in relation to Colo205 and normalized to GAPDH as a reference gene. RGS2 mRNA levels of SW480, HCT116 and Caco-2 were increased by 5.5-, 22.9-and 7.4-fold compared with that of Colo205 respectively, whereas RGS2 mRNA levels of SW620 and LoVo were decreased by 0.7-and 0.9-fold respectively ( Figure 1c) . For 118 immunostaining samples, it was shown that RGS2 expression was significantly associated with recurrence (Table 3) .
No correlation between RGS2 protein expression and clinicopathological parameters
A paraffin block is convenient to obtain and its clinicopathological information is relatively reliable, and we analysed the relationship between the RGS2 expression in paraffin-embedded specimens and the patients' clinical pathological characteristics. Positive staining was primarily observed in the cytoplasm of the cancer cells. Analysis of RGS2 expression in the 118 CRC tissues revealed that 67 % of samples demonstrated strong (2+ and 3+) intensity and 33 % low (-and +) intensity. Immunostaining of RGS2 protein is shown in Figures 3(c)-3(f) . No significant difference was observed regarding age, sex, size, histological type, lymphovascular and perineural invasion. However, the disease-free survival rate was significantly lower in patients with low RGS2 protein expression than those with high expression (P = 0.003). Table 2 shows the relationships between clinicopathological features and expression of RGS2 protein in 118 samples.
RGS2 expression and disease-free survival
Analysis of RGS2 expression in the 118 CRC tumours revealed that 39 samples showed weak staining and 79 samples showed strong staining. In all cases, RGS2 was mostly detected in the cytoplasm. Survival analysis was performed using follow-up data. Univariate analysis by the Kaplan-Meier plot revealed that weak RGS2 expression was significantly associated with unfavourable disease-free survival (P = 0.002). The Kaplan-Meier curves did not show any survival difference in CRC indicated by other parameters, including sex, age, tumour location, etc. A characteristic plot of RGS2 expression is shown in Figure 4 . Multivariate Cox analysis indicated that RGS2 expression and adjuvant chemotherapy were independent variables (P = 0.002). Weak RGS2 expression was associated with adverse disease-free survival (Table 4) .
DISCUSSION
CRC is one of the most aggressive cancers worldwide. Up to 50 % of patients undergoing surgery alone will show recurrence and ultimately die of metastatic diseases [3] . Adjuvant therapy is important for the clinical outcome of stage II and III cases, which represent approx. 70 % of CRC patients. New potential prognostic biomarkers are favourable to guide adjuvant therapy after primary surgery, especially for stage II patients. In the present study, we suggested that RGS2 is a potent candidate by showing its downexpression and association with an adverse prognosis in stage II and III CRC patients.
In the present study, for the first time we demonstrate the relationship between clinicopathological factors and survival time and RGS2 expression in stage II and III patients with CRC. The mRNA expression level of RGS2 in CRC tissues with recurrence was found to be significantly lower than those without recurrence. The same result was shown in CRC cell lines. Analysis of the relationship between the RGS2 protein expression in CRC tissues and the patients' clinical pathological characteristics revealed that RGS2 protein expression was associated with disease- free   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . survival, which confirmed the role of RGS2 in the recurrence of CRC. No correlation was found between RGS2 expression and the patient's age, tumour size, TNM stage and histological grade. Furthermore, survival analysis also showed that low RGS2 protein expression was associated with poor survival time.
In 118 samples, the median survival time is 5.233 years for stage II patients and 5.229 for stage III respectively, and statistical analysis showed that there is no significant difference (P = 0.744). The reason could be that chemotherapy prolonged the disease-free survival time in stage III patients. Moreover, multivariate Cox analysis indicated that chemotherapy was an independent protection factor and decreased by nearly 55 % the risk of recurrence [HR (hazard ratio) 0.448; P = 0.004]. To eliminate treatment bias caused by adjuvant chemotherapy, we analysed the correlation between RGS2 expression and survival time in stage II and III patients respectively. Results showed that chemotherapy did not influence the association between RGS2 expression and prognosis ( Figure 5) .
RGS2 was previously introduced as a possible tumour suppressor [18, 19] . In the present study, it was shown that RGS2 was down-regulated both in CRC tissues with recurrence and metastasis-derived cell lines, suggesting that it might be involved in metastasis. RGS2 is a regulator of GPCRs (G-protein-coupled receptors) that participate in diverse signalling pathways in cancers [20] , and it inhibits G q -coupled signalling in vivo [13, 21] . The RGS2-mediated inhibitory effect is presumably due to the occlusion of the binding site on G q for its primary effector phospholipase C by RGS2 [22] . Although the specific function of RGS2 in CRC progression is as yet unclear, our results support the concept that RGS2 inhibits G q -mediated carcinogenesis.
The most important finding in this study was that downregulated RGS2 expression in CRC patients was significantly Figure 4 The Kaplan-Meier estimated survival rates according to RGS2 expression Patients with low RGS2 expression (n = 39) showed significantly poorer prognosis than those with high RGS2 expression (n = 79) (P<0.05, log-rank test).
associated with poor prognosis and low disease-free survival rate ( Figure 4) . In CRC patients, partial stage II and all stage III cases could be considered for adjuvant therapy [23, 24] . However, the role of adjuvant chemotherapy in those patients with stage II tumours is still unclear [25] [26] [27] [28] . To select high-risk stage II CRC patients and maximize the benefits of adjuvant therapy, an independent prognostic marker could potentially be helpful for identifying aggressive phenotypes within stage II CRC.
In the present study, we have discussed the relationship between the level of RGS2 protein expression and tumour prognosis or recurrence in a relatively good sample size. We collected the experimental paraffin-embedded specimens between February 1993 and March 2004, and the followup time is relatively long. We do have sufficient data to discuss the correlations between RGS2 protein expression and survival time. We suggested that RGS2 is a potential marker for prognostic evaluation in patients with stage II and III CRC.
In conclusion, we suggest that RGS2 is down-regulated in CRC tissues with recurrence and CRC-metastasis-derived cell lines, and low RGS2 expression could be used as a predictor of recurrence and as a prognostic factor predicting survival of postoperative CRC patients. 
